Pain Medicine, Interventional Pain Medicine · Conyers, GA
NPI
1801138615
Since 2013
Specialty
Pain Medicine, Interventional Pain Medicine
Code 208VP0014X
Group practices
2
Medicare group memberships
Hospitals
6
Hospital affiliations
1388a Wellbrook Cir NE
Conyers, GA, 30012
Phone (404) 920-4950
Groups this clinician bills Medicare through
Medicare paid, 2024
$322K
3,856 services
Medicare patients, 2024
310
Average age 72
Drug cost, 2024
$442K
5,741 prescriptions
Company payments, 2025
$1,577
From 8 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by David W Neckman was code 80307 (drug tests), 627 times for 175 patients. In total David W Neckman billed 3,856 services in 46 codes, and Medicare paid $322K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-04-09.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 80307 Drug Tests | Office | 627 | 175 | $60.08 | $38K |
| 99213 Office E&M - Established | Office | 591 | 224 | $65.76 | $39K |
| 99214 Office E&M - Established | Office | 547 | 186 | $90.56 | $50K |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 378 | 76 | $47.69 | $18K |
| G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 365 | 121 | $191.28 | $70K |
| 96136 Behavioral Health Services | Office | 174 | 134 | $31.36 | $5,457 |
| 64483 Nerve Block Injection - Back | Facility | 125 | 86 | $103.51 | $13K |
| G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 122 | 47 | $153.46 | $19K |
| 27096 Joint Injection | Facility | 107 | 73 | $75.56 | $8,085 |
| G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 106 | 55 | $112.14 | $12K |
| 96127 Behavioral Health Services | Office | 59 | 48 | $3.68 | $217 |
| 64636 Destruction by Neurolytic Agent - Back | Facility | 57 | 39 | $53.50 | $3,049 |
| 64635 Destruction by Neurolytic Agent - Back | Facility | 53 | 40 | $177.53 | $9,409 |
| 64493 Nerve Block Injection - Back | Facility | 47 | 29 | $99.07 | $4,656 |
| 64484 Nerve Block Injection - Back | Facility | 46 | 34 | $37.37 | $1,719 |
By year: 2022 $251K for 2,810 services; 2023 $298K for 3,425 services; 2024 $322K for 3,856 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 80307 Drug Tests | 627 | 175 | $60.08 | $38K |
| G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | 365 | 121 | $191.28 | $70K |
| G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | 122 | 47 | $153.46 | $19K |
| G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | 106 | 55 | $112.14 | $12K |
Medicare prescription drug claims, 2024
In 2024, the drug David W Neckman prescribed most often to Medicare patients was Oxycodone-Acetaminophen (Oxycodone Hcl/Acetaminophen), with 1,584 prescriptions and refills. In total David W Neckman wrote 5,741 Medicare prescriptions that cost $442K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 1,584 | 1,585 | 246 | $54K |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 1,096 | 1,096 | 197 | $25K |
| Oxycodone Hcl Generic | 450 | 450 | 73 | $9,675 |
| Gabapentin Generic | 361 | 463 | 122 | $4,738 |
| Tizanidine Hcl Generic | 297 | 333 | 112 | $2,496 |
| Pregabalin Generic | 207 | 221 | 63 | $4,440 |
| Morphine Sulfate Er Morphine Sulfate | 161 | 161 | 25 | $3,626 |
| Xtampza Er Oxycodone Myristate | 154 | 154 | 19 | $64K |
| Tramadol Hcl Generic | 150 | 150 | 51 | $1,008 |
| Cyclobenzaprine Hcl Generic | 133 | 148 | 54 | $730 |
| Methocarbamol Generic | 100 | 106 | 42 | $740 |
| Meloxicam Generic | 93 | 111 | 42 | $232 |
| Buprenorphine Generic | 91 | 91 | 29 | $21K |
| Oxycontin Oxycodone Hcl | 55 | 56 | Under 11 | $19K |
| Lidocaine Generic | 49 | 58 | 17 | $7,805 |
Brand drugs: 374 claims; generic drugs: 5,367 claims; opioid claims: 4,036.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid David W Neckman $1,577 ($1,577 in general payments such as food, travel and fees) from 8 companies. The largest payer was Boston Scientific Corporation with $1,265.
| Company | Payments | Amount |
|---|---|---|
| Boston Scientific Corporation BSX | 13 | $1,265 |
| Forte Bio-Pharma LLC | 6 | $127 |
| BIOTRONIK NRO, Inc. | 3 | $66.77 |
| Collegium Pharmaceutical, Inc. COLL | 2 | $39.38 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC BHC | 1 | $22.22 |
| Vertex Pharmaceuticals Incorporated VRTX | 1 | $20.48 |
| Globus Medical, Inc. GMED | 1 | $17.88 |
| Abbott Laboratories ABT | 1 | $17.75 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.